Who is the CEO of Alt?

According to the DART company overview, Alt's representative director is 천병태 (name as registered in Korean). The company was founded on 2003-07-23.

Alt trades on the Korea Exchange KOSDAQ market under the ticker 172670. Its fiscal year ends in December.

Does Alt pay a dividend?

Alt did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Alt have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Revenue +30% (latest quarterly revenue up more than 30% year on year); Insider buying (officers or major shareholders reported adding shares (30 days)). These are factual flags, not investment advice.

Which companies are in the same industry as Alt?

Under the Korean Standard Industrial Classification recorded on DART, Alt is grouped with 23 other listed companies in semiconductors. The most covered in Korean news over the past 30 days are SK hynix, Shinsung E&g and Seoul Semiconductor.

Alt KRX:172670KOSDAQ

에이엘티 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h1

Articles, 7 days2

DART filings, 7 days1

Articles tracked30since Sep 11

In Q2 2026, Alt reported revenue of ₩16.4bn, up 46.4% year on year, and operating profit of ₩2.1bn. Alt (에이엘티) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 1 article. It was most often mentioned alongside Alteogen.

Filing signals Turnaround Revenue +30% Insider buying Dilution risk Screener

Alt quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩16.4bn	+46.4%	₩2.1bn margin 13.0%	₩1.5bn
Q1 2026	₩13.8bn	+37.0%	−₩858m margin −6.2%	−₩2.2bn
Q4 2025 derived	₩15.1bn	+51.9%	₩834m margin 5.5%	₩3.4bn
Q3 2025	₩12.0bn	+42.0%	−₩2.8bn margin −23.7%	−₩3.8bn
Q2 2025	₩11.2bn	+20.8%	−₩2.2bn margin −20.0%	−₩4.5bn
Q1 2025	₩10.1bn	+11.9%	−₩3.1bn margin −31.2%	−₩4.0bn
Q4 2024 derived	₩9.9bn	-13.8%	−₩2.8bn margin −28.4%	−₩2.0bn
Q3 2024	₩8.4bn	-12.9%	−₩4.1bn margin −48.2%	−₩2.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Alt top stories 2 weeks, by number of outlets

1
ALT 버리고 바이러스 역가로, B형간염 ‘회색지대’ 해소
1 outlets · 1 articlesFirst report Oct 21 05:59 의약뉴스
2
에이엘티, 122억원 규모 사모 전환사채 발행 결정
1 outlets · 1 articlesFirst report Oct 29 15:11 디지털투데이
3
알테오젠, ESMO서 ADC 피하주사 연구 공개···ALT-B4 적용해 안전성 개선 가능성 확인
1 outlets · 1 articlesFirst report Oct 26 08:45 녹색경제신문Alteogen

Latest Alt news Korean headlines

Oct 2915:11

에이엘티, 122억원 규모 사모 전환사채 발행 결정
디지털투데이
Oct 2608:45

알테오젠, ALT-B4 적용 ADC 피하주사 연구 공개…안전성 개선 확인
EBNAlteogen
Oct 2105:59

ALT 버리고 바이러스 역가로, B형간염 ‘회색지대’ 해소
의약뉴스
Oct 1109:51

Alteogen ALT-B4-based ‘Jemperli SC’ heads into clinical trials, GSK signals November start
더바이오
Oct 1007:55

키트루다SC 유럽 판결문 뜯어보니…ALT-B4 ‘5개 치환·페놀 안정성’이 침해 근거
메디코파마
Oct 812:00

알테오젠, 한 달 반 새 공장·증자·합병 결정…'ALT-B4 다음' 체제로 간다
스마트투데이Stake / acquisitionAlteogen
Oct 811:32
美선 특허 무효 잇따랐는데 유럽선 침해 인정…알테오젠 'ALT-B4' 특허전 변수
이데일리Alteogen
1 more on this story · 1 outlets
- 美선 특허 무효 잇따랐는데 유럽선 침해 인정…알테오젠 'ALT-B4' 특허전 변수이데일리 · Oct 8 11:32
Oct 810:11

에이엘티 천성민 상무이사, 소유 주식 수량 21만주 증가…소유 지분율 2.35%p 상승
디지털투데이
Oct 713:37

알테오젠 ALT-B4 적용 ‘젬퍼리SC’ 임상 간다…GSK, 11월 시작 예고
더바이오Alteogen
Oct 712:13

알테오젠, 'ALT-B4' 넘어 자체 개발·상업화 승부 … 2000억 실탄 장전
뉴데일리경제Alteogen
Oct 711:17

[유증+] '2000억 수혈' 알테오젠…ALT-B4 잇는 차세대 성장동력 확보
녹색경제신문Alteogen
Oct 117:30

Alteogen wins Japan sales approval for ALT-B4 subcutaneous ‘Keytruda’ formulation
더바이오
Sep 2815:25

에이엘티, 전환사채 60억원 소각…경영진 주식 매입도 이어져
파이낸셜포스트
Sep 2813:15
에이엘티, 60억원 규모 전환사채 콜옵션 행사
컨슈머타임스
2 more on this story · 2 outlets
- 에이엘티, 60억 규모 CB 콜옵션 행사뉴시스경제 · Sep 28 13:41
- 에이엘티, 60억원 규모 전환사채 콜옵션 행사뉴스핌 · Sep 28 13:50
Sep 2506:03

Major알테오젠, 주1회 성장호르몬 'ALT-P1' 2상 막바지…4Q 톱라인
메디파나뉴스Clinical trialAlteogen
Sep 2210:00

“알테오젠, ALT-B4 가치 본격 반영…2030년 로열티 6440억원”
한국경제Alteogen
Sep 2118:30

Alteogen files patent for ultra-long-acting platform ‘PCT,’ develops ‘once-monthly’ obesity drug ‘ALT-M5’
더바이오
Sep 2111:42

'키트루다 SC' 매출 뛰자 알테오젠도 웃는다…ALT-B4 수익 본궤도
메디파나뉴스Alteogen
Sep 2108:21

"알테오젠 ALT-B4 특허 2043년까지…장기 독점 효과 커질 것"-IBK
한국경제Alteogen
Sep 1813:58

Alteogen's New Long-Lasting Joint Technology: Revolutionizing Monthly Obesity Treatment with ALT-M5
뉴스1
Sep 1809:27
알테오젠 “ALT-B4 적용 키트루다 SC, 일본 판매 승인 획득”
한국경제Regulatory approvalAlteogen
3 more on this story · 3 outlets
- 알테오젠, ALT-B4 적용 피하주사 제형 ‘키트루다’ 日 판매 승인 획득더바이오 · Sep 18 09:28
- 알테오젠, ALT-B4 적용 '키트루다SC' 日 판매 승인 획득뉴스1 · Sep 18 09:29
- 알테오젠 ALT-B4 적용 키트루다SC, 일본 판매 승인청년의사 · Sep 18 16:41
Sep 1808:38

알테오젠, ‘장기지속형 접합체’ 국제특허출원 마쳐…월 1회 투약 비만치료제 ALT-M5 개발
메디컬투데이Alteogen
Sep 1708:37

Alteogen files global patent, targets once-monthly obesity drug with ALT-M5
조선비즈
Sep 1414:02

에이엘티, 제7회차 전환사채 콜옵션 행사로 60억원 규모 만기전 취득
디지털투데이

Articles per day 2 weeks

121

126

129

Company profile

CEO: 천병태
Industry: Semiconductors
Founded: 2003-07-23
Fiscal year-end: December
Head office: 충청북도 청주시
Website: alt-s.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

천병태29.85%
포커스자산운용5.76%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Semiconductors

All in industry

Company	Latest quarter op. profit	Articles 30d
SK hynix	₩60.5tn	2,918
Shinsung E&g	₩3.1bn	35
Seoul Semiconductor	₩3.5bn	33
HD Hyundai Energy Solutions	₩36.1bn	29
Hana Materials	₩26.0bn	27
Lumens	−₩1.8bn	16
Auk	₩1.3bn	15
Seoul Viosys	₩10.2bn	10

Compare Alt side by side with these companies

Alt DART filings

Oct 2914:50

Convertible bond 주요사항보고서(전환사채권발행결정)
Capital & M&A
Oct 809:59

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Oct 809:47

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 1710:33

5% ownership report [기재정정]주식등의대량보유상황보고서(약식)
Ownership reports
Sep 1516:31

5% ownership report 주식등의대량보유상황보고서(약식)
Ownership reports
Sep 1413:46

Other 전환사채(해외전환사채포함)발행후만기전사채취득 (제7회차)
Other
Sep 909:11

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 909:09

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Mentioned alongside 2 weeks

1 AlteogenKOSDAQ 1

Alt FAQ

Who is the CEO of Alt?: According to the DART company overview, Alt's representative director is 천병태 (name as registered in Korean). The company was founded on 2003-07-23.
Where is Alt listed?: Alt trades on the Korea Exchange KOSDAQ market under the ticker 172670. Its fiscal year ends in December.
What were Alt's latest quarterly results?: In Q2 2026, Alt reported revenue of ₩16.4bn, up 46.4% year on year, and operating profit of ₩2.1bn. Figures come from reports filed on DART.
Does Alt pay a dividend?: Alt did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Alt have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Revenue +30% (latest quarterly revenue up more than 30% year on year); Insider buying (officers or major shareholders reported adding shares (30 days)). These are factual flags, not investment advice.
Which companies are in the same industry as Alt?: Under the Korean Standard Industrial Classification recorded on DART, Alt is grouped with 23 other listed companies in semiconductors. The most covered in Korean news over the past 30 days are SK hynix, Shinsung E&g and Seoul Semiconductor.